Papua New GuineaTuberculosis profile
Population  2016 8.1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.6 (2.4–5) 44 (29–62)
Mortality (HIV+TB only) 0.82 (0.45–1.3) 10 (5.5–16)
Incidence  (includes HIV+TB) 35 (28–42) 432 (352–521)
Incidence (HIV+TB only) 3.6 (2–5.5) 44 (25–68)
Incidence (MDR/RR-TB)** 1.9 (1.2–2.6) 23 (15–32)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.8 (1.4–2.1) 11 (8.7–13) 13 (10–15)
Males 2 (1.6–2.4) 20 (16–24) 22 (18–27)
Total 3.8 (3–4.5) 31 (25–37) 35 (28–42)
TB case notifications, 2016  
Total cases notified 29 751
Total new and relapse 27 576
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 33%
          - % pulmonary 57%
          - % bacteriologically confirmed among pulmonary 31%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 79% (65–97)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.13 (0.08–0.18)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 699 7%
          - on antiretroviral therapy 642 92%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 200
(790–1 500)
Estimated % of TB cases with MDR/RR-TB 3.4% (1.7–5) 26% (15–36)  
% notified tested for rifampicin resistance     7 785
MDR/RR-TB cases tested for resistance to second-line drugs   210
Laboratory-confirmed cases MDR/RR-TB: 342, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 302, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New cases registered in 2015 74% 4 110
Previously treated cases registered in 2015 63% 661
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 52% 180
XDR-TB cases started on second-line treatment in 2014 40% 5
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 11
Funding source: 27% domestic, 73% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data